Focused Ultrasound-Enhanced Delivery of Abraxane to Intramedullary Spinal Cord Tumors.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42474477.
- Also identified by DOI 10.1227/neu.0000000000004164.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chemotherapeutic drug delivery to intramedullary spinal cord tumors (IMSCTs) is restricted by the blood-spinal cord barrier. Focused ultrasound (FUS), however, can transiently disrupt the blood-spinal cord barrier. Therefore, this study investigates the feasibility of using FUS-enhanced Abraxane (albumin-bound paclitaxel) delivery to improve the treatment of IMSCTs using a rodent model. Twenty-eight F344 rats received an intramedullary injection of 100 000 luciferase-tagged 9L gliosarcoma cells. Rats were classified into 4 cohorts: no-treatment, FUS, Abraxane, and FUS-enhanced Abraxane delivery. Treatments were administered on days 7, 14, and 21. Tumor burden was assessed weekly using bioluminescence-based imaging. Twice a week, nociceptive thresholds were assessed using the Von Frey Filament test, and motor function was assessed using the Basso-Beattie-Bresnahan locomotor scale. The FUS-enhanced Abraxane delivery cohort had significantly decreased tumor burden ([1.52 ± 0.69] × 106 photons/s) compared with the no-treatment ([9.03 ± 5.13] × 106 photons/s), FUS-only ([8.25 ± 1.58] × 106 photons/s) and Abraxane-only ([4.19 ± 1.91] × 106 photons/s) groups (day 18, P < .0001). Although all rodents initially demonstrated motor decline, the FUS-enhanced Abraxane group had complete return-to-baseline motor scores (21.0) by day 27, whereas the no-treatment (8.3 ± 1.5), FUS-only (6.0 ± 1.4), and Abraxane-only (16.3 ± 1.3) cohorts maintained decreased Basso, Beattie, and Bresnahan scale scores to day 48. Similarly, while all animals demonstrated initial hypersensitivity to pain, only the FUS-enhanced Abraxane group returned to baseline pain response by day 48 (17.4 ± 6.1 g) when compared with the no-treatment (7.0 ± 6.2 g), FUS-only (5.0 ± 1.4 g), and Abraxane-only (11.2 ± 7.5 g) cohorts. FUS-enhanced Abraxane delivery significantly reduced IMSCT tumor burden and improved neurological recovery over intravenous administration alone. Therefore, FUS-mediated chemotherapeutic drug delivery may represent a noninvasive, clinically relevant, and effective treatment paradigm for intramedullary pathologies.